{"Symbol": "BLRX", "AssetType": "Common Stock", "Name": "BioLineRx Ltd", "Description": "BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "Modi?in Technology Park, Modi?in, Israel, 7177871", "FullTimeEmployees": "42", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "38178788", "EBITDA": "-24702000", "PERatio": "None", "PEGRatio": "0.2", "BookValue": "1.485", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-2.835", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.3095", "ReturnOnEquityTTM": "-0.7667", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-2.325", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "11.33", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "1.2849", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "1.0061", "52WeekHigh": "3.642", "52WeekLow": "1.0609", "50DayMovingAverage": "2.0344", "200DayMovingAverage": "1.7813", "SharesOutstanding": "19767200", "SharesFloat": "18080894", "SharesShort": "430634", "SharesShortPriorMonth": "401200", "ShortRatio": "2.84", "ShortPercentOutstanding": "0.08", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "23.385", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:15", "LastSplitDate": "2019-07-15"}